ANGPTL3 Inhibitors
1 drugsAbout ANGPTL3
ANGPTL3 is a secreted protein that inhibits lipoprotein lipase (LPL) and endothelial lipase, key enzymes in lipid metabolism. By inhibiting these lipases, ANGPTL3 influences triglyceride and cholesterol levels in the blood.
ANGPTL3 is a therapeutic target for metabolic disorders, though currently there is no genetic evidence available linking it to specific diseases. The existence of an approved drug, EVKEEZA, underscores the therapeutic potential of modulating ANGPTL3 activity.
ANGPTL3 is targeted by one FDA-approved biologic drug, EVKEEZA (Regeneron), approved in 2021. This positions ANGPTL3 as a relatively new target in the metabolic disease space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top Drugs
Regeneron is the only company with an approved drug targeting ANGPTL3.
The market is highly concentrated, suggesting high barriers to entry or a first-mover advantage for Regeneron.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ANGPTL3, using biologic (other) modality.
The lack of small molecule or other modalities represents a whitespace opportunity for novel therapeutic development.
Clinical Trials 42 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 10 | 1 | 4 | 91% |
| Phase 2 | 11 | 7 | 1 | 3 | 88% |
| Phase 3 | 10 | 8 | 0 | 2 | 100% |
| Phase 4 | 6 | 4 | 2 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2021 - 2021)
The first and only drug targeting ANGPTL3, EVKEEZA, was approved in 2021.
The recent approval suggests a growing interest in ANGPTL3 as a target, but also indicates a potentially unsaturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 23 clinical trials targeting ANGPTL3.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities